Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

NCT06283641 · Completed

Last updated 2026-05-28

This trial is testing the safety and effectiveness of Saxenda® for managing weight in adults with obesity in real-world clinical settings in Taiwan.

Status Completed The study has finished.

Type Observational

Participants 300 people

Who can join Ages 12+ · all sexes

Timeline Started 2024-04 · est. completion 2025-01

Where 15 sites · Taiwan

What this study is testing ClinicalTrials.gov NCT06283641 ↗

Description as written by the study sponsor.

This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan. The participants will recieve Saxenda® treatment which is a medicine that doctors can already prescribe. The study will last for about 26 weeks.

Treatments tested

Liraglutide also known as Saxenda® Drug

Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.

Main thing measured	Incidence of adverse events (AEs) by preferred term (PT)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06283641 ↗